ADNeT in a Nutshell
• Clinical Quality Registry (CQR) for newly diagnosed
dementia or “mild cognitive impairment”
• Memory Clinics – expand, standardize and support
• Clinical Trial sites – expand and support
• Longitudinal (n=4,000) and Trial ready (n=500) cohorts –
blood, MRI, cognition, amyloid and tau PET, +/- CSF every 2 years
1.Provide IT infrastructure and support for the key ADNeT initiatives
2.Develop and harmonise innovative diagnostic technologies (i.e. PET
and MRI imaging and blood and CSF biomarkers).
The Australian Imaging Biomarkers and Lifestyle
Study of Ageing
Commenced late 2006
3,500 researchers granted access to AIBL data via
Includes access granted to 112 companies e.g.:
Abbott Labs, Abiant, ADM diagnostics, Astra Zeneca, Avid, BioClinica, Biogen Idec, Bristol-Myers Squibb, Cogstate Cytokinetics, Eisai, Elan, Eli Lilly, GE Health Care,
General Resonance, Genetech, Imorphics, Iris Biotechnologies, Janssen, Johnson Johnson, M and M Scientific, Merck & Co, Mimvista, Pentara Corp, Pfizer, Philips,
Predixion software, Rancho Biosciences, Servier, Siemens, Soft team solutions, UCB, United Biosource Corp.
AIBL has also received 250 Expressions of Interest for access to more detailed data.